Walter J. Urba

69.6k total citations · 4 hit papers
223 papers, 10.7k citations indexed

About

Walter J. Urba is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Walter J. Urba has authored 223 papers receiving a total of 10.7k indexed citations (citations by other indexed papers that have themselves been cited), including 141 papers in Oncology, 132 papers in Immunology and 57 papers in Molecular Biology. Recurrent topics in Walter J. Urba's work include Immunotherapy and Immune Responses (96 papers), Cancer Immunotherapy and Biomarkers (75 papers) and CAR-T cell therapy research (62 papers). Walter J. Urba is often cited by papers focused on Immunotherapy and Immune Responses (96 papers), Cancer Immunotherapy and Biomarkers (75 papers) and CAR-T cell therapy research (62 papers). Walter J. Urba collaborates with scholars based in United States, China and France. Walter J. Urba's co-authors include Bernard A. Fox, Hong‐Ming Hu, Dan L. Longo, John W. Smith, Brendan D. Curti, Steven O’Day, Ronald G. Steis, Omid Hamid, Jeffrey W. Clark and Andrew D. Weinberg and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Walter J. Urba

221 papers receiving 10.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

2004 598 citations Joseph I. Clark, Theodore F. Logan et al. profile →
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer

2022 319 citations Rom S. Leidner, Bernard A. Fox et al. profile →
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

2016 281 citations Neil H. Segal, Theodore F. Logan et al. Clinical Cancer Research profile →
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

2013 233 citations F. Stephen Hodi, Jeffrey S. Weber et al. profile →

Peers

Countries citing papers authored by Walter J. Urba

Since Specialization

Citations

This map shows the geographic impact of Walter J. Urba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Walter J. Urba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Walter J. Urba more than expected).

Fields of papers citing papers by Walter J. Urba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Walter J. Urba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Walter J. Urba. The network helps show where Walter J. Urba may publish in the future.

Co-authorship network of co-authors of Walter J. Urba

This figure shows the co-authorship network connecting the top 25 collaborators of Walter J. Urba. A scholar is included among the top collaborators of Walter J. Urba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Walter J. Urba. Walter J. Urba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical impact for advanced non-small-cell lung cancer patients tested using comprehensive genomic profiling at a large USA health care system 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Alessandro De Vita, Douglas Hanes, Bela Bapat, Shu‐Ching Chang, (unknown), Mark Schmidt, Cliff Wong, Hoifung Poon, Brock E. Schroeder, Roshanthi Weerasinghe, Rachel E. Sanborn, Rom S. Leidner, Walter J. Urba, Carlo Bifulco, Brian Piening	2
2	Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health System 2024 ·JCO Oncology Practice ·(unknown), (unknown), (unknown), Bela Bapat, Douglas Hanes, Shu‐Ching Chang, (unknown), Cliff Wong, Hoifung Poon, Brock E. Schroeder, Roshanthi Weerasinghe, Rom S. Leidner, Walter J. Urba, Carlo Bifulco, Brian Piening	2
3	SARS-CoV-2 Antibodies Detected in Mother’s Milk Post-Vaccination 2021 ·Journal of Human Lactation ·(unknown), Shawn M. Jensen, Walter J. Urba, Bernard A. Fox, Jason R. Baird	49
4	Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells 2021 ·Nature Communications ·Rebekka Duhen, Carmen Ballesteros‐Merino, Alexandra K. Frye, Eric Tran, Venkatesh Rajamanickam, Shu‐Ching Chang, Yoshinobu Koguchi, Carlo Bifulco, Brady Bernard, Rom S. Leidner, Brendan D. Curti, Bernard A. Fox, Walter J. Urba, R. Bryan Bell, Andrew D. Weinberg	114
5	Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma 2021 ·Journal for ImmunoTherapy of Cancer ·Rom S. Leidner, Marka R. Crittenden, Kristina H. Young, Hong Xiao, Yaping Wu, Marcus Couey, Ashish Patel, Allen Cheng, Amber L. Watters, Carlo Bifulco, George Morris, (unknown), (unknown), Walter J. Urba, Michael J. Gough, R. Bryan Bell	120
6	The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response 2020 ·Journal for ImmunoTherapy of Cancer ·Fernanda I. Arnaldez, Steven O’Day, Charles G. Drake, Bernard A. Fox, (unknown), Walter J. Urba, Vincenzo Montesarchio, Jeffrey S. Weber, Haiming Wei, Jon M. Wigginton, Paolo A. Ascierto	68
7	Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40 2017 ·Clinical Cancer Research ·David J. Messenheimer, Shawn M. Jensen, Michael Afentoulis, Keith W. Wegmann, Zipei Feng, David J. Friedman, Michael J. Gough, Walter J. Urba, Bernard A. Fox	234
8	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody breakdown → 2016 ·Clinical Cancer Research ·Neil H. Segal, Theodore F. Logan, F. Stephen Hodi, David F. McDermott, Ignacio Melero, Omid Hamid, Henrik Schmidt, Caroline Robert, Vanna Chiarion‐Sileni, Paolo A. Ascierto, Michele Maio, Walter J. Urba, Tara C. Gangadhar, Satyendra Suryawanshi, Jaclyn Neely, Maria Jure–Kunkel, Suba Krishnan, Holbrook E. Kohrt, Mario Sznol, Ronald Levy	281
9	Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab 2015 ·Cancer Research ·Yoshinobu Koguchi, Helena Hoen, Shelly Bambina, (unknown), (unknown), Brendan D. Curti, Walter J. Urba, Christina Milburn, Frances Rena Bahjat, Alan J. Korman, Keith S. Bahjat	39
10	Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy 2011 ·Clinical Cancer Research ·Yuhuan Li, Lixin Wang, Puiyi Pang, Zhi-Hua Cui, Sandra Aung, Daniel Haley, Bernard A. Fox, Walter J. Urba, Hong‐Ming Hu	115
11	Efficient Cross-presentation Depends on Autophagy in Tumor Cells 2008 ·Cancer Research ·Yuhuan Li, Lixin Wang, Guojun Yang, Hao Fang, Walter J. Urba, Hong‐Ming Hu	246
12	Phenotype and Functional Characterization of Long-term gp100-Specific Memory CD8+ T Cells in Disease-Free Melanoma Patients Before and After Boosting Immunization 2008 ·Clinical Cancer Research ·Edwin Walker, Daniel Haley, Ulf Petrausch, Kevin Floyd, William L. Miller, (unknown), (unknown), Bernard A. Fox, Walter J. Urba	24
13	Phase I/II Trial of Outpatient PEG-interferon With Interleukin-2 in Advanced Renal Cell Carcinoma: A Cytokine Working Group Study 2007 ·Journal of Immunotherapy ·Joseph I. Clark, (unknown), Jeffrey A. Sosman, Theodore F. Logan, Kim Margolin, Janice P. Dutcher, Walter J. Urba, Marc S. Ernstoff, David F. McDermott, (unknown), Michael B. Atkins	4
14	Regression of a Mammary Adenocarcinoma in STAT6−/− Mice Is Dependent on the Presence of STAT6-Reactive T Cells 2003 ·The Journal of Immunology ·Shawn M. Jensen, Sybren L. Meijer, Robert A. Kurt, Walter J. Urba, Hong‐Ming Hu, Bernard A. Fox	21
15	TNF Plays an Essential Role in Tumor Regression after Adoptive Transfer of Perforin/IFN-γ Double Knockout Effector T Cells 2003 ·The Journal of Immunology ·Christian Poehlein, Hong‐Ming Hu, (unknown), Ilka Assmann, W. Gregory Alvord, Walter J. Urba, Bernard A. Fox	56
16	CD28, TNF Receptor, and IL-12 Are Critical for CD4-Independent Cross-Priming of Therapeutic Antitumor CD8+ T Cells 2002 ·The Journal of Immunology ·Hong‐Ming Hu, H. Winter, Jun Ma, Michael Croft, Walter J. Urba, Bernard A. Fox	17
17	Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice 2000 ·International Journal of Cancer ·Robert A. Kurt, Rachel J. Whitaker, (unknown), Steven K. Seung, Walter J. Urba	15
18	Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity 2000 ·The Journal of Immunology ·Andrew D. Weinberg, (unknown), Rodney A. Prell, Arden M. Morris, (unknown), John T. Vetto, Walter J. Urba, Gregory Alvord, Campbell Bunce, John Shields	315
19	Divergent Roles for CD4+ T Cells in the Priming and Effector/Memory Phases of Adoptive Immunotherapy 2000 ·The Journal of Immunology ·Hong‐Ming Hu, H. Winter, Walter J. Urba, Bernard A. Fox	87
20	Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. 1992 ·PubMed ·C. Ewel, Walter J. Urba, William C. Kopp, John W. Smith, Ronald G. Steis, Jeffrey L. Rossio, Dan L. Longo, (unknown), W. Gregory Alvord, Carl Pinsky	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact